participating in another rct in the past 12 months; known allergy to nitazoxanide severely reduced lv function; severely reduced renal function; pregnancy or breast feeding; diagnosis of any other active infection (viral, bacterial, fungal or caused by another pathogen, except the one studied in the trial); history of hiv 1 and/or 2 (anti-hiv-1,2) and/or htlv i and ii positive; ongoing antineoplastic treatment with chemotherapy or radiation therapy; diagnose of severe autoimmune diseases in immunosuppression; transplanted patients; any other clinical condition which, in the opinion of the principal investigator, would not allow safe completion of the protocol and safe administration of the investigational products

participating in another rct in the past 12 months; known allergy to nitazoxanide severely reduced lv function; severely reduced renal function; pregnancy or breast feeding; diagnosis of any other active infection (viral, bacterial, fungal or caused by another pathogen, except the one studied in the trial); history of hiv 1 and/or 2 (anti-hiv-1,2) and/or htlv i and ii positive; ongoing antineoplastic treatment with chemotherapy or radiation therapy; diagnose of severe autoimmune diseases in immunosuppression; transplanted patients; any other clinical condition which, in the opinion of the principal investigator, would not allow safe completion of the protocol and safe administration of the investigational products

1. participating in another rct in the past 12 months; 2. known allergy to nitazoxanide 3. severely reduced lv function; 4. severely reduced renal function; 5. pregnancy or breast feeding; 6. diagnosis of any other active infection (viral, bacterial, fungal or caused by another pathogen, except the one studied in the trial); 7. history of hiv 1 and/or 2 (anti-hiv-1,2) and/or htlv i and ii positive; 8. ongoing antineoplastic treatment with chemotherapy or radiation therapy; 9. diagnose of severe autoimmune diseases in immunosuppression; 10. transplanted patients; 11. any other clinical condition which, in the opinion of the principal investigator, would not allow safe completion of the protocol and safe administration of the investigational products

1. participating in another rct in the past 12 months; 2. known allergy to nitazoxanide 3. severely reduced lv function; 4. severely reduced renal function; 5. pregnancy or breast feeding; 6. diagnosis of any other active infection (viral, bacterial, fungal or caused by another pathogen, except the one studied in the trial); 7. history of hiv 1 and/or 2 (anti-hiv-1,2) and/or htlv i and ii positive; 8. ongoing antineoplastic treatment with chemotherapy or radiation therapy; 9. diagnose of severe autoimmune diseases in immunosuppression; 10. transplanted patients; 11. any other clinical condition which, in the opinion of the principal investigator, would not allow safe completion of the protocol and safe administration of the investigational products